Global Molecular Diagnostics Market Size study, by Product (Instruments, Reagents), by Test Location (Point of Care, Self-Test), by Technology, by Application and Regional Forecasts 2022-2032
Global Molecular Diagnostics Market is valued approximately at USD 24.77 billion in 2023 and is anticipated to grow with a steady growth rate of more than 3.97% over the forecast period 2024-2032. Molecular diagnostics has emerged as the linchpin of modern healthcare, enabling early and precise detection of genetic disorders, infectious diseases, and cancer through advanced nucleic acid testing technologies. Leveraging the analytical power of PCR, next-generation sequencing, and microarray technologies, molecular diagnostics facilitates personalized treatment regimens and real-time monitoring of disease progression. As the demand for rapid, reliable, and minimally invasive diagnostic tools intensifies, particularly in post-pandemic healthcare infrastructures, the market is pivoting toward decentralization, automation, and integration with digital ecosystems, thereby unlocking unprecedented clinical potential and operational efficiencies.
A wave of transformative forces is driving the expansion of the molecular diagnostics industry. These include rising incidences of chronic and infectious diseases, increased adoption of precision medicine, and a growing focus on preventive healthcare. In parallel, the burgeoning interest in self-testing and home-based diagnostics—fueled by consumer health awareness and convenience—has catalyzed a shift toward compact, user-friendly platforms. Healthcare providers are integrating point-of-care diagnostic devices within primary care settings to ensure timely therapeutic interventions and curb disease outbreaks. This is particularly evident in the uptake of molecular testing for respiratory infections, sexually transmitted diseases, and cancer risk profiling. Furthermore, government support and investment in molecular screening initiatives have broadened public access to these technologies across both developed and emerging markets.
Despite robust momentum, several structural challenges impede the market’s full-scale evolution. High initial setup costs, complex reimbursement landscapes, and regulatory hurdles in assay development continue to burden manufacturers, particularly small and mid-sized players. Moreover, technological disparities across low-resource settings limit adoption, thereby amplifying global health inequities. To overcome these barriers, key stakeholders are pivoting toward cost-effective, scalable, and modular diagnostic solutions. Innovations in multiplex testing, AI-driven diagnostics, and integrated lab-on-a-chip devices are not only reducing time-to-results but are also enabling broader clinical applicability across a spectrum of diseases.
Market frontrunners are forging strategic collaborations, mergers, and technology licensing deals to stay competitive and expedite product rollouts. Many are investing in proprietary platforms capable of high-throughput testing, while others are enhancing assay sensitivity and specificity for earlier-stage disease detection. The convergence of cloud computing and diagnostics is further empowering real-time data sharing and analysis, enhancing the precision and speed of decision-making for healthcare professionals. Digital connectivity is also enabling remote patient monitoring and mobile-based testing, establishing a new paradigm in decentralized healthcare delivery.
From a geographical standpoint, North America currently commands a dominant share of the molecular diagnostics market, driven by a highly developed healthcare ecosystem, sophisticated reimbursement structures, and early technology adoption. The United States continues to lead in terms of innovation and research output. Europe follows closely, with countries like Germany and the UK actively investing in population-wide genetic screening programs. Meanwhile, the Asia Pacific region is projected to register the fastest growth, underpinned by expanding healthcare access, government-led genomics initiatives, and an increasing burden of infectious diseases. Latin America and the Middle East & Africa are also showing promising growth trajectories, especially as public health authorities ramp up diagnostic capacities in response to global health emergencies.
Major market player included in this report are:
By Product
North America
A wave of transformative forces is driving the expansion of the molecular diagnostics industry. These include rising incidences of chronic and infectious diseases, increased adoption of precision medicine, and a growing focus on preventive healthcare. In parallel, the burgeoning interest in self-testing and home-based diagnostics—fueled by consumer health awareness and convenience—has catalyzed a shift toward compact, user-friendly platforms. Healthcare providers are integrating point-of-care diagnostic devices within primary care settings to ensure timely therapeutic interventions and curb disease outbreaks. This is particularly evident in the uptake of molecular testing for respiratory infections, sexually transmitted diseases, and cancer risk profiling. Furthermore, government support and investment in molecular screening initiatives have broadened public access to these technologies across both developed and emerging markets.
Despite robust momentum, several structural challenges impede the market’s full-scale evolution. High initial setup costs, complex reimbursement landscapes, and regulatory hurdles in assay development continue to burden manufacturers, particularly small and mid-sized players. Moreover, technological disparities across low-resource settings limit adoption, thereby amplifying global health inequities. To overcome these barriers, key stakeholders are pivoting toward cost-effective, scalable, and modular diagnostic solutions. Innovations in multiplex testing, AI-driven diagnostics, and integrated lab-on-a-chip devices are not only reducing time-to-results but are also enabling broader clinical applicability across a spectrum of diseases.
Market frontrunners are forging strategic collaborations, mergers, and technology licensing deals to stay competitive and expedite product rollouts. Many are investing in proprietary platforms capable of high-throughput testing, while others are enhancing assay sensitivity and specificity for earlier-stage disease detection. The convergence of cloud computing and diagnostics is further empowering real-time data sharing and analysis, enhancing the precision and speed of decision-making for healthcare professionals. Digital connectivity is also enabling remote patient monitoring and mobile-based testing, establishing a new paradigm in decentralized healthcare delivery.
From a geographical standpoint, North America currently commands a dominant share of the molecular diagnostics market, driven by a highly developed healthcare ecosystem, sophisticated reimbursement structures, and early technology adoption. The United States continues to lead in terms of innovation and research output. Europe follows closely, with countries like Germany and the UK actively investing in population-wide genetic screening programs. Meanwhile, the Asia Pacific region is projected to register the fastest growth, underpinned by expanding healthcare access, government-led genomics initiatives, and an increasing burden of infectious diseases. Latin America and the Middle East & Africa are also showing promising growth trajectories, especially as public health authorities ramp up diagnostic capacities in response to global health emergencies.
Major market player included in this report are:
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Danaher Corporation
- bioM?rieux SA
- QIAGEN N.V.
- Siemens Healthineers AG
- Hologic, Inc.
- Agilent Technologies, Inc.
- Illumina, Inc.
- Grifols, S.A.
- Cepheid (A Danaher Company)
- Bio-Rad Laboratories, Inc.
- GenMark Diagnostics, Inc.
- Myriad Genetics, Inc.
By Product
- Instruments
- Reagents
- Point of Care
- Self-Test
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Microarray
- In Situ Hybridization
- Others
- Infectious Diseases
- Oncology
- Genetic Testing
- Blood Screening
- Others
North America
- U.S.
- Canada
- UK
- Germany
- France
- Spain
- Italy
- Rest of Europe
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia Pacific
- Brazil
- Mexico
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
- Historical year – 2022
- Base year – 2023
- Forecast period – 2024 to 2032
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Danaher Corporation
- bioM?rieux SA
- QIAGEN N.V.
- Siemens Healthineers AG
- Hologic, Inc.
- Agilent Technologies, Inc.
- Illumina, Inc.
- Grifols, S.A.
- Cepheid (A Danaher Company)
- Bio-Rad Laboratories, Inc.
- GenMark Diagnostics, Inc.
- Myriad Genetics, Inc.
CHAPTER 1. GLOBAL MOLECULAR DIAGNOSTICS MARKET EXECUTIVE SUMMARY
1.1. Global Molecular Diagnostics Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Product
1.3.2. By Test Location
1.3.3. By Technology
1.3.4. By Application
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL MOLECULAR DIAGNOSTICS MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL MOLECULAR DIAGNOSTICS MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Rising Incidence of Chronic & Infectious Diseases
3.1.2. Adoption of Precision Medicine & Preventive Healthcare
3.1.3. Growth of Decentralized & Digital Diagnostic Platforms
3.2. Market Challenges
3.2.1. High Initial Setup Costs & Reimbursement Complexity
3.2.2. Regulatory Hurdles in Assay Development
3.2.3. Technological Disparities in Low-Resource Settings
3.3. Market Opportunities
3.3.1. Multiplex Testing & Lab-on-a-Chip Innovations
3.3.2. AI-Driven Diagnostics & Data Analytics
3.3.3. Expansion of Self-Testing & Home-Based Platforms
CHAPTER 4. GLOBAL MOLECULAR DIAGNOSTICS MARKET INDUSTRY ANALYSIS
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Adaptation of Porter’s Model
4.1.7. Porter’s Five Forces Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspectives
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE & FORECASTS BY PRODUCT (2022–2032)
5.1. Segment Dashboard
5.2. Instruments: Revenue Trend Analysis, 2022 & 2032 (USD Million)
5.3. Reagents: Revenue Trend Analysis, 2022 & 2032 (USD Million)
CHAPTER 6. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE & FORECASTS BY TEST LOCATION (2022–2032)
6.1. Segment Dashboard
6.2. Point of Care: Revenue Trend Analysis, 2022 & 2032 (USD Million)
6.3. Self-Test: Revenue Trend Analysis, 2022 & 2032 (USD Million)
CHAPTER 7. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE & FORECASTS BY TECHNOLOGY (2022–2032)
7.1. Segment Dashboard
7.2. Polymerase Chain Reaction (PCR): Revenue Trend Analysis, 2022 & 2032 (USD Million)
7.3. Next-Generation Sequencing (NGS): Revenue Trend Analysis, 2022 & 2032 (USD Million)
7.4. Microarray: Revenue Trend Analysis, 2022 & 2032 (USD Million)
7.5. In Situ Hybridization: Revenue Trend Analysis, 2022 & 2032 (USD Million)
7.6. Others: Revenue Trend Analysis, 2022 & 2032 (USD Million)
CHAPTER 8. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE & FORECASTS BY APPLICATION (2022–2032)
8.1. Segment Dashboard
8.2. Infectious Diseases: Revenue Trend Analysis, 2022 & 2032 (USD Million)
8.3. Oncology: Revenue Trend Analysis, 2022 & 2032 (USD Million)
8.4. Genetic Testing: Revenue Trend Analysis, 2022 & 2032 (USD Million)
8.5. Blood Screening: Revenue Trend Analysis, 2022 & 2032 (USD Million)
8.6. Others: Revenue Trend Analysis, 2022 & 2032 (USD Million)
CHAPTER 9. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE & FORECASTS BY REGION (2022–2032)
9.1. North America Market
9.1.1. U.S. Market
9.1.2. Canada Market
9.2. Europe Market
9.2.1. UK Market
9.2.2. Germany Market
9.2.3. France Market
9.2.4. Spain Market
9.2.5. Italy Market
9.2.6. Rest of Europe Market
9.3. Asia Pacific Market
9.3.1. China Market
9.3.2. India Market
9.3.3. Japan Market
9.3.4. Australia Market
9.3.5. South Korea Market
9.3.6. Rest of Asia Pacific Market
9.4. Latin America Market
9.4.1. Brazil Market
9.4.2. Mexico Market
9.5. Middle East & Africa Market
9.5.1. Saudi Arabia Market
9.5.2. South Africa Market
9.5.3. Rest of Middle East & Africa Market
CHAPTER 10. COMPETITIVE INTELLIGENCE
10.1. Key Company SWOT Analysis
10.1.1. F. Hoffmann-La Roche Ltd
10.1.2. Thermo Fisher Scientific Inc.
10.1.3. Abbott Laboratories
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. F. Hoffmann-La Roche Ltd
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. Danaher Corporation
10.3.3. bioM?rieux SA
10.3.4. QIAGEN N.V.
10.3.5. Siemens Healthineers AG
10.3.6. Hologic, Inc.
10.3.7. Agilent Technologies, Inc.
10.3.8. Illumina, Inc.
10.3.9. Grifols, S.A.
10.3.10. Cepheid (Danaher)
10.3.11. Bio-Rad Laboratories, Inc.
10.3.12. GenMark Diagnostics, Inc.
10.3.13. Myriad Genetics, Inc.
CHAPTER 11. RESEARCH PROCESS
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
1.1. Global Molecular Diagnostics Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Product
1.3.2. By Test Location
1.3.3. By Technology
1.3.4. By Application
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL MOLECULAR DIAGNOSTICS MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL MOLECULAR DIAGNOSTICS MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Rising Incidence of Chronic & Infectious Diseases
3.1.2. Adoption of Precision Medicine & Preventive Healthcare
3.1.3. Growth of Decentralized & Digital Diagnostic Platforms
3.2. Market Challenges
3.2.1. High Initial Setup Costs & Reimbursement Complexity
3.2.2. Regulatory Hurdles in Assay Development
3.2.3. Technological Disparities in Low-Resource Settings
3.3. Market Opportunities
3.3.1. Multiplex Testing & Lab-on-a-Chip Innovations
3.3.2. AI-Driven Diagnostics & Data Analytics
3.3.3. Expansion of Self-Testing & Home-Based Platforms
CHAPTER 4. GLOBAL MOLECULAR DIAGNOSTICS MARKET INDUSTRY ANALYSIS
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Adaptation of Porter’s Model
4.1.7. Porter’s Five Forces Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspectives
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE & FORECASTS BY PRODUCT (2022–2032)
5.1. Segment Dashboard
5.2. Instruments: Revenue Trend Analysis, 2022 & 2032 (USD Million)
5.3. Reagents: Revenue Trend Analysis, 2022 & 2032 (USD Million)
CHAPTER 6. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE & FORECASTS BY TEST LOCATION (2022–2032)
6.1. Segment Dashboard
6.2. Point of Care: Revenue Trend Analysis, 2022 & 2032 (USD Million)
6.3. Self-Test: Revenue Trend Analysis, 2022 & 2032 (USD Million)
CHAPTER 7. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE & FORECASTS BY TECHNOLOGY (2022–2032)
7.1. Segment Dashboard
7.2. Polymerase Chain Reaction (PCR): Revenue Trend Analysis, 2022 & 2032 (USD Million)
7.3. Next-Generation Sequencing (NGS): Revenue Trend Analysis, 2022 & 2032 (USD Million)
7.4. Microarray: Revenue Trend Analysis, 2022 & 2032 (USD Million)
7.5. In Situ Hybridization: Revenue Trend Analysis, 2022 & 2032 (USD Million)
7.6. Others: Revenue Trend Analysis, 2022 & 2032 (USD Million)
CHAPTER 8. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE & FORECASTS BY APPLICATION (2022–2032)
8.1. Segment Dashboard
8.2. Infectious Diseases: Revenue Trend Analysis, 2022 & 2032 (USD Million)
8.3. Oncology: Revenue Trend Analysis, 2022 & 2032 (USD Million)
8.4. Genetic Testing: Revenue Trend Analysis, 2022 & 2032 (USD Million)
8.5. Blood Screening: Revenue Trend Analysis, 2022 & 2032 (USD Million)
8.6. Others: Revenue Trend Analysis, 2022 & 2032 (USD Million)
CHAPTER 9. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE & FORECASTS BY REGION (2022–2032)
9.1. North America Market
9.1.1. U.S. Market
9.1.2. Canada Market
9.2. Europe Market
9.2.1. UK Market
9.2.2. Germany Market
9.2.3. France Market
9.2.4. Spain Market
9.2.5. Italy Market
9.2.6. Rest of Europe Market
9.3. Asia Pacific Market
9.3.1. China Market
9.3.2. India Market
9.3.3. Japan Market
9.3.4. Australia Market
9.3.5. South Korea Market
9.3.6. Rest of Asia Pacific Market
9.4. Latin America Market
9.4.1. Brazil Market
9.4.2. Mexico Market
9.5. Middle East & Africa Market
9.5.1. Saudi Arabia Market
9.5.2. South Africa Market
9.5.3. Rest of Middle East & Africa Market
CHAPTER 10. COMPETITIVE INTELLIGENCE
10.1. Key Company SWOT Analysis
10.1.1. F. Hoffmann-La Roche Ltd
10.1.2. Thermo Fisher Scientific Inc.
10.1.3. Abbott Laboratories
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. F. Hoffmann-La Roche Ltd
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. Danaher Corporation
10.3.3. bioM?rieux SA
10.3.4. QIAGEN N.V.
10.3.5. Siemens Healthineers AG
10.3.6. Hologic, Inc.
10.3.7. Agilent Technologies, Inc.
10.3.8. Illumina, Inc.
10.3.9. Grifols, S.A.
10.3.10. Cepheid (Danaher)
10.3.11. Bio-Rad Laboratories, Inc.
10.3.12. GenMark Diagnostics, Inc.
10.3.13. Myriad Genetics, Inc.
CHAPTER 11. RESEARCH PROCESS
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
LIST OF TABLES
TABLE 1. Global Molecular Diagnostics market, report scope
TABLE 2. Global Molecular Diagnostics market estimates & forecasts by Region 2022–2032 (USD Million)
TABLE 3. Global Molecular Diagnostics market estimates & forecasts by Product 2022–2032 (USD Million)
TABLE 4. Global Molecular Diagnostics market estimates & forecasts by Test Location 2022–2032 (USD Million)
TABLE 5. Global Molecular Diagnostics market estimates & forecasts by Technology 2022–2032 (USD Million)
TABLE 6. Global Molecular Diagnostics market estimates & forecasts by Application 2022–2032 (USD Million)
TABLE 7. Global Molecular Diagnostics market by segment, estimates & forecasts, 2022–2032 (USD Million)
TABLE 8. Global Molecular Diagnostics market by region, estimates & forecasts, 2022–2032 (USD Million)
TABLE 9. U.S. Molecular Diagnostics market estimates & forecasts, 2022–2032 (USD Million)
TABLE 10. U.S. market estimates & forecasts by segment 2022–2032 (USD Million)
TABLE 11. Canada market estimates & forecasts, 2022–2032 (USD Million)
TABLE 12. Canada market estimates & forecasts by segment 2022–2032 (USD Million)
TABLE 13. UK market estimates & forecasts, 2022–2032 (USD Million)
TABLE 14. Germany market estimates & forecasts, 2022–2032 (USD Million)
TABLE 15. France market estimates & forecasts, 2022–2032 (USD Million)
TABLE 16. Spain market estimates & forecasts, 2022–2032 (USD Million)
TABLE 17. Italy market estimates & forecasts, 2022–2032 (USD Million)
TABLE 18. Asia Pacific market estimates & forecasts, 2022–2032 (USD Million)
TABLE 19. Latin America market estimates & forecasts, 2022–2032 (USD Million)
TABLE 20. Middle East & Africa market estimates & forecasts, 2022–2032 (USD Million)
TABLE 1. Global Molecular Diagnostics market, report scope
TABLE 2. Global Molecular Diagnostics market estimates & forecasts by Region 2022–2032 (USD Million)
TABLE 3. Global Molecular Diagnostics market estimates & forecasts by Product 2022–2032 (USD Million)
TABLE 4. Global Molecular Diagnostics market estimates & forecasts by Test Location 2022–2032 (USD Million)
TABLE 5. Global Molecular Diagnostics market estimates & forecasts by Technology 2022–2032 (USD Million)
TABLE 6. Global Molecular Diagnostics market estimates & forecasts by Application 2022–2032 (USD Million)
TABLE 7. Global Molecular Diagnostics market by segment, estimates & forecasts, 2022–2032 (USD Million)
TABLE 8. Global Molecular Diagnostics market by region, estimates & forecasts, 2022–2032 (USD Million)
TABLE 9. U.S. Molecular Diagnostics market estimates & forecasts, 2022–2032 (USD Million)
TABLE 10. U.S. market estimates & forecasts by segment 2022–2032 (USD Million)
TABLE 11. Canada market estimates & forecasts, 2022–2032 (USD Million)
TABLE 12. Canada market estimates & forecasts by segment 2022–2032 (USD Million)
TABLE 13. UK market estimates & forecasts, 2022–2032 (USD Million)
TABLE 14. Germany market estimates & forecasts, 2022–2032 (USD Million)
TABLE 15. France market estimates & forecasts, 2022–2032 (USD Million)
TABLE 16. Spain market estimates & forecasts, 2022–2032 (USD Million)
TABLE 17. Italy market estimates & forecasts, 2022–2032 (USD Million)
TABLE 18. Asia Pacific market estimates & forecasts, 2022–2032 (USD Million)
TABLE 19. Latin America market estimates & forecasts, 2022–2032 (USD Million)
TABLE 20. Middle East & Africa market estimates & forecasts, 2022–2032 (USD Million)
LIST OF FIGURES
FIG 1. Global Molecular Diagnostics market, research methodology
FIG 2. Global market estimation techniques
FIG 3. Global market size estimates & forecast methods
FIG 4. Global market, key trends 2023
FIG 5. Global market, growth prospects 2022–2032
FIG 6. Porter’s Five Forces model
FIG 7. PESTEL analysis
FIG 8. Value chain analysis
FIG 9. Market by Product, 2022 & 2032 (USD Million)
FIG 10. Market by Test Location, 2022 & 2032 (USD Million)
FIG 11. Market by Technology, 2022 & 2032 (USD Million)
FIG 12. Market by Application, 2022 & 2032 (USD Million)
FIG 13. Regional snapshot 2022 & 2032
FIG 14. North America market 2022 & 2032 (USD Million)
FIG 15. Europe market 2022 & 2032 (USD Million)
FIG 16. Asia Pacific market 2022 & 2032 (USD Million)
FIG 17. Latin America market 2022 & 2032 (USD Million)
FIG 18. Middle East & Africa market 2022 & 2032 (USD Million)
FIG 19. Company market share analysis (2023)
FIG 20. Digital integration & decentralization trends (2023)
FIG 1. Global Molecular Diagnostics market, research methodology
FIG 2. Global market estimation techniques
FIG 3. Global market size estimates & forecast methods
FIG 4. Global market, key trends 2023
FIG 5. Global market, growth prospects 2022–2032
FIG 6. Porter’s Five Forces model
FIG 7. PESTEL analysis
FIG 8. Value chain analysis
FIG 9. Market by Product, 2022 & 2032 (USD Million)
FIG 10. Market by Test Location, 2022 & 2032 (USD Million)
FIG 11. Market by Technology, 2022 & 2032 (USD Million)
FIG 12. Market by Application, 2022 & 2032 (USD Million)
FIG 13. Regional snapshot 2022 & 2032
FIG 14. North America market 2022 & 2032 (USD Million)
FIG 15. Europe market 2022 & 2032 (USD Million)
FIG 16. Asia Pacific market 2022 & 2032 (USD Million)
FIG 17. Latin America market 2022 & 2032 (USD Million)
FIG 18. Middle East & Africa market 2022 & 2032 (USD Million)
FIG 19. Company market share analysis (2023)
FIG 20. Digital integration & decentralization trends (2023)
